Prostate Cancer

The addition of darolutamide to androgen deprivation therapy and docetaxel generated better overall survival vs placebo with ADT and docetaxel in patients with metastatic castration-sensitive prostate cancer.

The combination of niraparib and abiraterone acetate and prednisone led to a significant improvement in radiographic progression-free survival vs placebo plus abiraterone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.

Olaparib in combination with abiraterone acetate led to a 34% reduction in the risk of radiographic disease progression or death compared with placebo and abiraterone as a first-line treatment for patients with metastatic castration-resistant prostate cancer, according to results of the phase 3 PROpel trial.

Treatment with apalutamide, an androgen receptor inhibitor, was associated with a deep PSA response leading to beneficial outcomes in patient-related end points.

A greater portion of patients with metastatic castration-sensitive prostate cancer achieved an early and deep prostate-specific antigen reduction from baseline of 90% or more when treated with apalutamide compared with enzalutamide.

Fred Saad, MD, FRCS, discusses the efficacy of olaparib plus abiraterone acetate as first-line treatment in metastatic castration-resistant prostate cancer.

Axel Merseburger, MD, PhD, discusses results from the phase 3b PRESIDE trial in metastatic castration-resistant prostate cancer.

Andrew J. Armstrong, MD, MSc, discusses findings from a post-hoc analysis of the phase 3 ARCHES trial in metastatic hormone-sensitive prostate cancer.

Ashutosh K. Tewari, MD, discusses the factors to consider when deciding on a robotic radical prostatectomy​ for a patient with prostate cancer.

The FDA has granted a breakthrough device designation to the TriNetra-Prostate blood test for use in the detection of early-stage prostate cancer.

Nima Sharifi, MD, director, discusses the methodologies utilized when evaluating the correlation between gut microbiome and fatal prostate cancer.

Dhyan Chandra, PhD, discusses recent findings relating to low levels of cytochrome C in Black men with prostate cancer, plus plans for future research on this topic.

Nima Sharifi, MD, discusses the rationale to evaluate the correlation between the gut microbiome and the aggressiveness of prostate cancer.

Anna Woloszynska, PhD, discusses the role of community outreach in addressing disparities in prostate cancer.

Dhyan Chandra, PhD, discusses the need for resources to evaluate racial disparities in prostate cancer.

Aaron LeBeau, PhD, discusses the potential wide applicability of shark antibodies in developing imaging and therapeutic strategies in prostate cancer.

Anna Woloszynska, PhD, discusses continued research efforts investigating racial disparities in prostate cancer.

Dhyan Chandra, PhD, discusses evaluating biological differences between African American and Caucasian men with prostate cancer.

Aaron LeBeau, PhD, discusses the potential of shark variable domain of new antigen receptor proteins in prostate cancer.

Dhyan Chandra, PhD, discusses the potential to assess mitochondrial function to inform outcomes in prostate cancer.

Anna Woloszynska, PhD, discusses the need to assess biological factors of racial disparities in prostate cancer.

Hope S. Rugo, MD, FASCO, Rita Nanda, MD, William J. Gradishar, MD, and Tiffany A. Traina, MD discuss the selective immunomodulating microtubule-binding agent plinabulin, plus several other novel chemoprotective therapies under exploration, including trilaciclib.

Leonard G. Gomella, MD, discusses the challenges of optimizing prostate-specific antigen as a biomarker in prostate cancer.

Amado J. Zurita-Saavedra, MD, discusses the potential benefits of augmenting therapy earlier on in the treatment of patients with newly diagnosed metastatic prostate cancer.

Michael J. Morris, MD, discusses logistical challenges of utilizing Lutetium 177 PSMA-617 in prostate cancer.

The combination of pembrolizumab and enzalutamide continued to demonstrate antitumor activity in patients with metastatic castration-resistant prostate cancer who were previously treated with abiraterone acetate, according to data from cohort C of the phase 1b/2 KEYNOTE-365 trial.

Bilal A. Siddiqui, MD, discusses the nuances of defining the characteristics of nonmetastatic castration-resistant prostate cancer.

Black men with localized prostate cancer who had been treated with definitive radiotherapy had a lower likelihood of experiencing biochemical recurrence, distant metastasis, and prostate cancer–specific mortality compared with White men despite having more aggressive disease.

New grants from the U.S. Department of Defense and American Cancer Society will fund work by two Roswell Park Comprehensive Cancer Center teams focused on understanding and eliminating prostate cancer health disparities.

Amado J. Zurita-Saavedra, MD, discusses emerging frontline therapies in metastatic hormone-sensitive prostate cancer.